Home › Funds › Caligan Partners LP › VRDN
Caligan Partners LP position in VRDN
VIRIDIAN THERAPEUTICS INC · Health Care
Caligan Partners LP reported holding 3,080,262 shares of VRDN (VIRIDIAN THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$57.3M, representing 3.51% of its reported portfolio and ranking #8 among its reported holdings. Caligan Partners LP has disclosed VRDN holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Caligan Partners LP's VRDN position evolved
Caligan Partners LP first disclosed a stake in VRDN in Q2 2026 at 2,193,981 shares (US$40.3M). The position peaked in Q3 2026 at 3,080,262 shares, worth US$57.3M. Across 2 filings, Caligan Partners LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 3,080,262 shares valued at US$57.3M — an increase of 886,281 shares quarter over quarter.. Notable position changes include a 40% increase in Q3 2026 (shares rose 45% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 2.19M | $40.30M | New |
| Q3 2026 | 3.08M | $57.34M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About VRDN and 13F data
VRDN (VIRIDIAN THERAPEUTICS INC) is a Health Care company. 40 other funds we track also report a position in VRDN — the largest reported positions include Paradigm Biocapital Advisors LP (US$227.1M), Bellevue Group AG (US$146.4M), Kynam Capital Management, LP (US$126.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding VRDN
- Paradigm Biocapital Advisors LP 12.41M sh · $227.08M · Q3 2026
- Bellevue Group AG 7.11M sh · $146.38M · Q3 2026
- Kynam Capital Management, LP 6.15M sh · $126.59M · Q3 2026
- Fairmount Funds Management LLC 5.09M sh · $104.82M · Q3 2026
- RTW INVESTMENTS, LP 4.98M sh · $102.03M · Q3 2026
- RA CAPITAL MANAGEMENT, L.P. 5.96M sh · $81.79M · Q3 2026
- Novo Holdings A/S 4.87M sh · $78.92M · Q3 2026
- Venrock Adviser, LLC 3.26M sh · $67.08M · Q3 2026
- Deep Track Capital, LP 3.83M sh · $64.34M · Q3 2026
- Atlas Venture Life Science Advisors, LLC 4.50M sh · $61.83M · Q3 2026
- Context Capital Management, LLC 49.00M sh · $56.47M · Q3 2026
- Avoro Capital Advisors LLC 2.50M sh · $51.48M · Q3 2026
More on Caligan Partners LP
FAQ
How long has Caligan Partners LP held VRDN?
Caligan Partners LP has disclosed VRDN holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is Caligan Partners LP's current position in VRDN?
As of Q3 2026, Caligan Partners LP holds 3.08M shares of VRDN (VIRIDIAN THERAPEUTICS INC), valued at $57.34M, representing 3.51% of its reported portfolio and ranking #8.
Has Caligan Partners LP been buying or selling VRDN?
In the latest 13F filing (Q3 2026), Caligan Partners LP increased its position in VRDN. The position peaked in Q3 2026 at 3.08M shares.
Which other funds hold VRDN?
Other major institutional holders of VRDN include Paradigm Biocapital Advisors LP, Bellevue Group AG, Kynam Capital Management, LP, among 40 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.